KreaMedica Holdings Inc. represents a new breed of biotech investor grounded in the principle of “smart money.” We pair capital with a collaborative drug development team, creating a differentiated and integrated investment approach.
KreaMedica Holdings Inc. invests in fast-growing biotechnology companies that develop innovative drugs or technologies. We focus on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit growth potential. Furthermore, we focus on the earlier phases of development, where most of the funding challenges exist.
Our Portfolio of Investments
Cytonus is developing Cargocytes, functional enucleated synthetic cells that actively transport to the target tissue to deliver disease-specific payloads within hours of intravenous administration.
Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise.
InnovoTEX is an oncology therapeutic company developing its proprietary platform of uniquely designed novel assets. A clinical lead candidate that induces ribosomal biosynthesis stress to activate wt-p53 and circumvent platinum resistance in wt-p53 refractory cancers.
Atriva pursues a new approach to develop treatments for viral infections by combining antiviral and anti-inflammatory activity in one tablet. The novel approach provides a broadly efficacious treatment against viral infections such as COVID-19 and influenza.
Acesis Holdings Corporation and its wholly-owned subsidiary Acesis Biomed US, is an emerging, pre-phase 1 biotechnology company focused on men’s health developing novel, non-steroid treatments for low testosterone (T) levels in males known as T-deficiency or male hypogonadism and related co-morbidities
OrthoTreat revolutionizes the field of bone regeneration by harnessing physiological regulation to enhance the natural bone healing process. A distinctive approach synergises two FDA-approved Active Pharmaceutical Ingredients (APIs), with complementary biochemical mechanisms, to forge an innovative, efficient, and safe treatment pathway for bone-related conditions.
After more than 20 years of Apoptosis research, Medraxa brings the lessons learned back to patients, teaching the immune system to tolerate its tissues and fight cancer through the Annexin Checkpoint System.
